To investigate the clinical implications of EDEM gene upregulation, we looked at EDEM1/2/3 mRNA expression in relation to disease-free survival in 471 prostate cancer patients in the TGCA PRAD cohort [28] (Figure 1C–E). The gene discussed is EDEM1; the disease is prostate adenocarcinoma.